Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Klatskin Tumor 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Adrenocortical Carcinoma 1

Interventions

Paclitaxel 328Carboplatin 323Bevacizumab 171Gemcitabine 106liposomal doxorubicin 104pembrolizumab 101Cyclophosphamide 96Topotecan 94olaparib 92Cisplatin 92niraparib 69Docetaxel 57Taxes 52Doxorubicin 51Drug Therapy 45fludarabine 40Filgrastim 39Nivolumab 37Magnetic Resonance Spectroscopy 34Surveys and Questionnaires 33Specimen Handling 33Etoposide 32Hyperthermic Intraperitoneal Chemotherapy 31Blood Specimen Collection 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Cytoreduction Surgical Procedures 25Albumin-Bound Paclitaxel 25durvalumab 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × N-Ac-CHAVC-NH2 × Clear all
NCT00265057 2010-12-28

Study of ADH-1 Given Intravenously to Patients With Solid Tumors

Adherex Technologies, Inc.

Phase 1/2 Completed
GynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡